secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2022-05-11T23:59:59+00:00
Accession:  0000950170-22-009315
Event type: leadership
Sentiment:  positive
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

David Johnson appointed to Caribou board; brings 30 years biopharma commercial experience
--------------------------------------------------------------------------------

- Board expanded from 7 to 8 directors; Johnson appointed effective May 11, 2022.
- Annual cash compensation of $40,000; initial option for 44,000 shares vesting over 3 years.
- Johnson was CCO at Global Blood Therapeutics and spent 15 years at Gilead in commercial roles.
- No immediate committee assignments; standard indemnification agreement entered.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000095017022009315/0000950170-22-009315-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000095017022009315/crbu-20220510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-009315

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer